806 Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients...
806 Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
About this item
Full title
Author / Creator
Publisher
Kidlington: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
Introduction/BackgroundHRD identifies HGOC patients most likely to benefit from PARPi. Unlike commercially available genomic-scar HRD tests(CT), functional testing by RAD51, has potential to provide real-time readout of current HR status and may be more reliable to detect HRD.MethodologyThis single-institution study aims to assess immunofluorescenc...
Alternative Titles
Full title
806 Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2955870810
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2955870810
Other Identifiers
ISSN
1048-891X
E-ISSN
1525-1438
DOI
10.1136/ijgc-2024-ESGO.990
